tirzepatide
tirzepatide: developed by 1 company · 53 clinical trials tracked · 1 FDA decision.
tirzepatide evidence translation
What we can confirm
1 FDA record · 53 tracked trials
What it means
What to watch
Prepared research question
How could tirzepatide → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 10 study sponsors
Related indications
Development Pipeline (3)
| Company | Phase |
|---|---|
| ELI LILLY & Co (LLY) for the treatment of adults with type 2 diabetes in combinat… | Approved |
| ELI LILLY & Co (LLY) Obesity; Psoriasis; Type 2 Diabetes | Phase 4 |
| ELI LILLY & Co (LLY) for the treatment of adults with type 2 diabetes in combinat… | Approved |
Clinical Trials (53)showing 10 most recent
Tirzepatide for Treatment of CCCA
Primary endpoint: Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score
Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Primary endpoint: Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable)
A Phase IV Placebo-controlled Single Center Trial for Tirzepatide in Idiopathic Intracranial Hypertension Trial (TIIHT)
Primary endpoint: Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Primary endpoint: Change from baseline in body weight at 48 weeks
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Primary endpoint: Anti-proliferative effect of Tirzepatide
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial
Primary endpoint: Change in 6-Minute Walk Distance
A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Primary endpoint: Percent change in liver fat
Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial
Primary endpoint: Daytime Time-in-Range
Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial
Primary endpoint: Change from Baseline in Sperm Concentration (million/mL) at Week 32 of Intervention
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
Primary endpoint: Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss
FDA Decisions1 records
Frequently asked questions
Who is developing tirzepatide?
tirzepatide is being developed by ELI LILLY & Co.
How many clinical trials involve tirzepatide?
BioSniper tracks 53 clinical trials involving tirzepatide.
What is tirzepatide's latest FDA decision?
The most recent tracked FDA decision for tirzepatide is Approval, dated May 13, 2022.